Invitae Revenue and Competitors
Estimated Revenue & Valuation
- Invitae's estimated annual revenue is currently $434.8M per year.
- Invitae received $143.8M in venture funding in March 2019.
- Invitae's estimated revenue per employee is $233,115
- Invitae's total funding is $2B.
- Invitae's current valuation is $2.7B. (January 2022)
Employee Data
- Invitae has 1865 Employees.
- Invitae grew their employee count by -14% last year.
Invitae Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $37.9M | 265 | 29% | N/A | N/A |
#2 | $258.5M | 898 | -10% | $1.1B | $2.4B |
#3 | $121.9M | 384 | 21% | N/A | N/A |
#4 | $564.8M | 3872 | 6% | $404.1M | $6.4B |
#5 | $4280M | 11139 | -4% | $28M | $63.3B |
#6 | $391.6M | 1036 | 6% | N/A | N/A |
#7 | $343.9M | 3176 | 7% | $550M | $7.9B |
What Is Invitae?
Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world's genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. Choose from our curated panels or design your own test for the same low price. Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.
keywords:Biotechnology,E-Commerce,Healthcare,Medical Diagnostics,Pharmaceuticals
$2B
Total Funding
1865
Number of Employees
$434.8M
Revenue (est)
-14%
Employee Growth %
$2.7B
Valuation
N/A
Accelerator
Invitae's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Genetic Counselor/Variant Interpretation Scientist | Reveal Email/Phone |
2 | Bioinformatics Engineer | Reveal Email/Phone |
3 | Associate Director - Clinical Genomics Operations | Reveal Email/Phone |
4 | Regional Manager | Reveal Email/Phone |
5 | Clinical Genomics Scientific Curator | Reveal Email/Phone |
6 | Regional Manager, Oncology TMC/South Central | Reveal Email/Phone |
7 | Senior Software Engineer | Reveal Email/Phone |
8 | Regional Manager | Reveal Email/Phone |
9 | Customer Success Manager | Reveal Email/Phone |
10 | Senior Director, Research & Development Genomics | Reveal Email/Phone |
Invitae News
Colliers secures lease renewal and expansion for medical genetic testing company Invitae in Iselin. By. Linda Lindner(Iselin). -. April 26, 2022.
Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into...
Los Angeles-based healthcare venture capital investor Wavemaker Three-Sixty Health has scored an exit in its portfolio, through the acquisition of Ciitizen by Invitae. According to Wavemaker Health, Ciitizen was its third investment in its fund. Ciitizen is a consumer health technology company, ...
SAN FRANCISCO, Sept. 7, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to bui ...
SAN FRANCISCO, Sept. 7, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to b ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $379.6M | 1870 | 6% | N/A |
#2 | $134.3M | 1882 | 3% | $152.7M |
#3 | $750M | 1883 | N/A | N/A |
#4 | $169.1M | 1908 | 9% | $1.5B |
#5 | $4800M | 1912 | -39% | $1.5B |
Invitae Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-12-11 | $40.0M | E | Article | |
| 2014-10-14 | $120.0M | F | Multiple | Article |
| 2016-11-18 | $44.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2018-02-28 | $40.0M | Undisclosed | Oxford Finance, LLC | Article |
| 2018-03-27 | $57.5M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2019-03-05 | $143.8M | Undisclosed | J.P. Morgan Securities LLC | Article |